Nothing Special   »   [go: up one dir, main page]

DK1192185T3 - Apo-2L-receptoragonist og CPT-11-synergisme - Google Patents

Apo-2L-receptoragonist og CPT-11-synergisme

Info

Publication number
DK1192185T3
DK1192185T3 DK00941233T DK00941233T DK1192185T3 DK 1192185 T3 DK1192185 T3 DK 1192185T3 DK 00941233 T DK00941233 T DK 00941233T DK 00941233 T DK00941233 T DK 00941233T DK 1192185 T3 DK1192185 T3 DK 1192185T3
Authority
DK
Denmark
Prior art keywords
cpt
apo
synergism
receptor agonist
methods
Prior art date
Application number
DK00941233T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Ralph H Schwall
Mark C Benyunes
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1192185T3 publication Critical patent/DK1192185T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK00941233T 1999-06-09 2000-06-07 Apo-2L-receptoragonist og CPT-11-synergisme DK1192185T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13824099P 1999-06-09 1999-06-09

Publications (1)

Publication Number Publication Date
DK1192185T3 true DK1192185T3 (da) 2006-10-23

Family

ID=22481115

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00941233T DK1192185T3 (da) 1999-06-09 2000-06-07 Apo-2L-receptoragonist og CPT-11-synergisme

Country Status (13)

Country Link
US (3) US20040228868A1 (da)
EP (1) EP1192185B1 (da)
JP (1) JP2003505344A (da)
AT (1) ATE330972T1 (da)
AU (1) AU5596500A (da)
CA (1) CA2375149A1 (da)
DE (1) DE60028971T2 (da)
DK (1) DK1192185T3 (da)
ES (1) ES2267547T3 (da)
IL (1) IL146491A0 (da)
PT (1) PT1192185E (da)
WO (1) WO2000075191A2 (da)
ZA (1) ZA200002867B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747635B2 (en) 1997-03-17 2002-05-16 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
EP1196191A4 (en) * 1999-05-04 2004-03-24 Human Genome Sciences Inc DEATH DOMAIN CONTAINING RECEPTOR 5
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
EP1303293B1 (en) * 2000-07-27 2008-12-03 Genentech, Inc. Sequential administration of cpt-11 and apo-2l polypeptide
ES2304235T3 (es) 2000-10-20 2008-10-01 Chugai Seiyaku Kabushiki Kaisha Anticuerpo agonista de tpo modificado.
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
RO123525B1 (ro) * 2001-11-01 2013-04-30 Uab Research Foundation Metodă in vitro de inducere selectivă a apoptozei sau de inhibare a proliferării celulelor ţintă care exprimă dr5 şi compoziţie pentru inducerea selectivă a apoptozei cuprinzând o combinaţie de anticorpi
EP1450847B1 (en) 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
EP1465925A4 (en) * 2001-12-20 2006-02-08 Human Genome Sciences Inc "ANTIBODIES THAT IMMUNE SPECIFICALLY TO TRAIL RECEPTORS"
AU2003247609A1 (en) 2002-06-24 2004-01-06 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
CA2501616C (en) * 2002-10-08 2015-05-12 Immunomedics, Inc. Antibody therapy
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US20080206229A1 (en) 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
NZ550518A (en) * 2004-03-23 2009-11-27 Biogen Idec Inc Agents that cross link TNF receptors for treating cancer
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1846034A4 (en) 2005-02-02 2010-11-10 Uab Research Foundation AGENTS AND METHODS OF REDUCING THE RESISTANCE TO APOPTOSIS INDUCING DEATH RECEPTOR AGONISTS
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
WO2006132363A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
CN107188963A (zh) 2010-10-29 2017-09-22 第三共株式会社 新的抗dr5抗体
JP2014513128A (ja) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド 血管破壊剤とその使用
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US20150030832A1 (en) * 2012-08-03 2015-01-29 Mazda Motor Corporation Transparent layered structure and method for producing the same
CN108884158A (zh) 2015-12-01 2018-11-23 根马布有限公司 抗死亡受体抗体及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
EP0981618B2 (en) * 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
CA2301202A1 (en) * 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
JP2002500877A (ja) * 1998-01-26 2002-01-15 ジェネンテク・インコーポレイテッド 細胞死レセプター４（ｄｒ４）に対する抗体及びその使用
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002069995A2 (en) * 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer

Also Published As

Publication number Publication date
ES2267547T3 (es) 2007-03-16
CA2375149A1 (en) 2000-12-14
IL146491A0 (en) 2002-07-25
JP2003505344A (ja) 2003-02-12
EP1192185A2 (en) 2002-04-03
DE60028971D1 (de) 2006-08-03
ZA200002867B (en) 2001-12-07
WO2000075191A2 (en) 2000-12-14
US20040228868A1 (en) 2004-11-18
DE60028971T2 (de) 2007-02-08
PT1192185E (pt) 2006-11-30
US20090041788A1 (en) 2009-02-12
EP1192185B1 (en) 2006-06-21
AU5596500A (en) 2000-12-28
WO2000075191A3 (en) 2001-05-10
ATE330972T1 (de) 2006-07-15
US20070026000A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
DK1192185T3 (da) Apo-2L-receptoragonist og CPT-11-synergisme
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
AP2002002458A0 (en) Compounds for the treatment of ischemia.
EA200101166A1 (ru) Ингибиторы металлопротеаз
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
NO20052922D0 (no) Fremgangsmate og sammensetninger for induksjon av apoptosis hos cancerceller
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
ID25853A (id) Penghambat saluran kalium
DK1663242T3 (da) 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
TR200103216T2 (tr) Pirimidinon bileşimleri
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
TW200738288A (en) Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same
SE9900961D0 (sv) Novel compounds
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
WO2002066415A3 (en) Non-steroidal modulators of estrogen receptors
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento
SE9802207D0 (sv) Novel compounds
UA3706U (uk) Спосіб розмноження ожини